Bulletin: AbbVie's $8.7 Billion Acquisition Of Cerevel Therapeutics Will Absorb Its Remaining Debt Capacity At The Current Rating - S&P Global Ratings’ Credit Research

Bulletin: AbbVie's $8.7 Billion Acquisition Of Cerevel Therapeutics Will Absorb Its Remaining Debt Capacity At The Current Rating

Bulletin: AbbVie's $8.7 Billion Acquisition Of Cerevel Therapeutics Will Absorb Its Remaining Debt Capacity At The Current Rating - S&P Global Ratings’ Credit Research
Bulletin: AbbVie's $8.7 Billion Acquisition Of Cerevel Therapeutics Will Absorb Its Remaining Debt Capacity At The Current Rating
Published Dec 07, 2023
2 pages (1252 words) — Published Dec 07, 2023
Price Free  |  Buy this Report Now

About This Report

  
Abstract:

NEW YORK (S&P Global Ratings) Dec. 7, 2023--S&P Global Ratings today said that AbbVie Inc. (A-/Stable/A-2) has sufficient capacity at the current rating to complete its announced $8.7 billion acquisition of Cerevel Therapeutics, a clinical-stage biopharmaceutical company focused on neuroscience. As part of the transaction, the company will acquire Emraclidine, which is currently being tested as a treatment for schizophrenia in two registration-enabling phase-II clinical trials that are expected to be completed in 2024. This product has a different mechanism of action and appears to have a more favorable side-effect profile than other currently approved schizophrenia drugs. Emraclidine is also in a phase-I clinical trial for the treatment of Alzheimer's disease-related psychosis. We see the potential for this product to

  
Brief Excerpt:

...AbbVie's $8.7 Billion Acquisition Of Cerevel Therapeutics Will Absorb Its Remaining Debt Capacity At The Current Rating...

  
Report Type:

Bulletin

Ticker
0330845Z
Issuer
AbbVie Inc.
GICS
Biotechnology (35201010)
Sector
Global Issuers
Country
United States
Region
United States
Format:
PDF Adobe Acrobat
Buy Now

AbbVie Inc. – 2024/12/03 – US$ 500.00

AbbVie Inc. – 2025/04/08 – US$ 500.00

AbbVie Inc. – 2023/11/14 – US$ 500.00

AbbVie Inc. – 2022/05/12 – US$ 500.00

AbbVie Inc. – 2021/06/10 – US$ 500.00

AbbVie Inc. – 2020/10/19 – US$ 500.00

More from S&P Global Ratings’ Credit Research

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Bulletin: AbbVie's $8.7 Billion Acquisition Of Cerevel Therapeutics Will Absorb Its Remaining Debt Capacity At The Current Rating" Dec 07, 2023. Alacra Store. May 21, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Bulletin-AbbVie-s-8-7-Billion-Acquisition-Of-Cerevel-Therapeutics-Will-Absorb-Its-Remaining-Debt-Capacity-At-The-Current-Rating-3099846>
  
APA:
S&P Global Ratings’ Credit Research. (). Bulletin: AbbVie's $8.7 Billion Acquisition Of Cerevel Therapeutics Will Absorb Its Remaining Debt Capacity At The Current Rating Dec 07, 2023. New York, NY: Alacra Store. Retrieved May 21, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Bulletin-AbbVie-s-8-7-Billion-Acquisition-Of-Cerevel-Therapeutics-Will-Absorb-Its-Remaining-Debt-Capacity-At-The-Current-Rating-3099846>
  
Free
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.